Takeda Pharmaceutical (TAK) Long-Term Deferred Tax: 2018-2025

  • Takeda Pharmaceutical's Long-Term Deferred Tax fell 8.57% to $2.4 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $2.4 billion, marking a year-over-year decrease of 8.57%. This contributed to the annual value of $2.4 billion for FY2025, which is 10.88% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Long-Term Deferred Tax stood at $2.4 billion for Q1 2025, which was down 8.57% from $2.7 billion recorded in Q1 2024.
  • In the past 5 years, Takeda Pharmaceutical's Long-Term Deferred Tax registered a high of $3.3 billion during Q1 2021, and its lowest value of $2.4 billion during Q1 2025.
  • In the last 3 years, Takeda Pharmaceutical's Long-Term Deferred Tax had a median value of $2.7 billion in 2024 and averaged $2.6 billion.
  • Per our database at Business Quant, Takeda Pharmaceutical's Long-Term Deferred Tax climbed by 18.11% in 2021 and then fell by 11.30% in 2023.
  • Over the past 5 years, Takeda Pharmaceutical's Long-Term Deferred Tax (Quarterly) stood at $3.3 billion in 2021, then decreased by 6.66% to $3.1 billion in 2022, then decreased by 11.30% to $2.8 billion in 2023, then declined by 3.95% to $2.7 billion in 2024, then dropped by 8.57% to $2.4 billion in 2025.
  • Its last three reported values are $2.4 billion in Q1 2025, $2.7 billion for Q1 2024, and $2.8 billion during Q1 2023.